Immunometabolic Therapies for Alzheimer’s Disease
Official title: Immunometabolic Therapeutics for Alzheimer's Disease
Funded at Biotherapeutics, INC. · NIH-11403648 · Data updated 2026-11-12
A new oral treatment approach for Alzheimer’s disease aims to protect brain cells by correcting immune and metabolic problems.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biotherapeutics, INC. NIH-funded |
| Lab location | 1 site (Blacksburg, UNITED STATES) |
| Project start | September 18, 2026 |
| Project end | September 17, 2027 |
| Funding year | 2026 |
| Award (this year) | $500,000 |
| NIH project number | 1R43AG102078-01 |
| Project ID | NIH-11403648 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are people with or at risk for Alzheimer’s disease who could participate in future trials or benefit from downstream therapeutic development.
✕Less likely to help
Early-stage preclinical work may not yet benefit patients directly until later trial phases.
What this research studies
This project focuses on a novel immunometabolic target to slow or prevent neurodegeneration in Alzheimer’s disease, using advanced computer modeling and laboratory experiments. It plans to design first-in-class oral therapeutics that modulate brain lipid metabolism and glial cell activity to reduce inflammation and oxidative stress. The work will involve studies in Alzheimer’s disease models and may inform future human trials for patients with Alzheimer's dementia.
Why it matters
Potential benefit: If successful, this work could lead to safer, targeted oral therapies that slow neurodegeneration and improve quality of life for people with Alzheimer's disease.
How similar studies have gone: Prior research in immunometabolic approaches to neurodegenerative diseases has shown promise in preclinical models, but Alzheimer’s-specific human data are pending.
Where this research is happening
-
Biotherapeutics, INC.
Blacksburg, United States Active
Researchers
- Principal investigator: Leber, Andrew — Biotherapeutics, INC.
- Study coordinator: Leber, Andrew
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.